STOCK TITAN
  1. Home
  2. Financials
  3. INBP
  4. Revenue

Integrated BioPharma (INBP) Revenue by Year

INBP OTC

Integrated BioPharma Inc generated $43.9M in revenue in fiscal year 2026. This represents a decrease of 19.3% from the prior fiscal year. The table below carries 15 fiscal years, from 2012 to 2026, and the quarters Integrated BioPharma Inc has filed alongside them.

FY2026 annual
Revenue $43.9M
YoY -19.3%
5Y CAGR -7.1%
Source SEC Filings (10-K/10-Q) Latest period FY2026, ended Jun 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

INBP Revenue by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY2610-KFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-KFY1810-KFY1710-KFY1710-KFY1510-KFY1410-KFY1310-KFY1210-K
Revenue$43.9M-19.3%$54.4M+8.0%$50.3M-0.7%$50.7M-9.9%$56.2M-11.5%$63.6M+20.4%$52.8M+5.6%$50.0M+14.3%$43.7M-6.9%$47.0M$35.7M$37.5M+11.3%$33.7M+0.2%$33.6M-8.1%$36.6M

INBP Revenue by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ4'2610-KQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-Q
Revenue$9.8M-30.9%$10.1M-27.5%$11.3M-10.6%$12.7M-6.8%$14.2M+11.2%$13.9M+6.1%$12.6M+9.6%$13.6M+5.4%$12.7M-1.9%$13.1M+0.4%$11.5M-6.1%$12.9M+4.8%

What revenue means

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it.

More Integrated BioPharma Inc financials

Frequently Asked Questions

Integrated BioPharma Inc generated $43.9M in revenue in fiscal year 2026.

Integrated BioPharma Inc (INBP) revenue fell by 19.3% year over year, from $54.4M to $43.9M in fiscal year 2026.

Across the 15 fiscal years this page covers, Integrated BioPharma Inc (INBP) revenue went from $36.6M in fiscal year 2012 to $43.9M in fiscal year 2026.

Integrated BioPharma Inc (INBP) reported $9.8M in revenue in Q4 2026. This represents a decrease of 30.9% from the same quarter a year earlier.

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it. This page lists what Integrated BioPharma Inc (INBP) reported on that line in every period on record.